- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05111574
Usando nivolumab sozinho ou com cabozantinib para prevenir o retorno do melanoma da mucosa após a cirurgia
Um estudo randomizado de fase II do adjuvante nivolumab com ou sem cabozantinib em pacientes com melanoma de mucosa ressecado
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.
Visão geral do estudo
Status
Condições
- Melanoma Mucoso
- Melanoma Anal
- Melanoma da Bexiga
- Melanoma Cervical
- Melanoma Esofágico
- Melanoma da Vesícula Biliar
- Melanoma da Mucosa da Cavidade Bucal
- Melanoma da Mucosa Peniana
- Melanoma retal
- Melanoma Mucoso Recorrente
- Melanoma da Mucosa Nasossinusal
- Melanoma uretral
- Melanoma Vaginal
- Melanoma Vulvar
- Melanoma mucosa de cabeça e pescoço
- Melanoma da mucosa nasofaríngea
- Melanoma mucosa do sistema urinário
Intervenção / Tratamento
- Procedimento: Computed Tomography
- Procedimento: Magnetic Resonance Imaging
- Medicamento: Cabozantinib S-malate
- Procedimento: Echocardiography Test
- Procedimento: Positron Emission Tomography
- Biológico: Nivolumab
- Procedimento: Bone Scan
- Procedimento: Biospecimen Collection
- Medicamento: Placebo Administration
Descrição detalhada
PRIMARY OBJECTIVE:
I. To compare the efficacy of adjuvant nivolumab (480 mg every [q]4 weeks) versus nivolumab plus cabozantinib s-malate (cabozantinib) (40 mg daily) in patients with mucosal melanoma.
SECONDARY OBJECTIVES:
I. To compare overall survival between the two adjuvant therapies. II. To evaluate the adverse effects in each arm. III. To assess the correlation between PD-L1 expression in tumor cells with survival (recurrence free survival [RFS] and overall survival [OS]).
IV. To evaluate the overall response rate (ORR), duration of response (DOR), progression free survival (PFS), and OS of nivolumab plus cabozantinib in patients who cannot undergo gross total resection of disease or have metastatic disease at baseline.
V. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
OUTLINE: Patients whose tumor has been fully removed by surgery are randomized to Arm 1 or Arm 2. Patients whose tumor has not been fully removed by surgery or has spread are assigned to Arm 3.
ARM 1: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and cabozantinib orally (PO) once daily (QD) of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
ARM 3: Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo echocardiogram (ECHO) during screening and as clinically indicated throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial.
After completion of study treatment, patients are followed up every 3 months until disease progression, and then every 6 months for up to 5 years from registration or until death.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H 8L6
- Ottawa Hospital and Cancer Center-General Campus
-
Toronto, Ontario, Canadá, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canadá, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Canadá, H3T 1E2
- Jewish General Hospital
-
-
-
-
California
-
Auburn, California, Estados Unidos, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Estados Unidos, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Fremont, California, Estados Unidos, 94538
- Palo Alto Medical Foundation-Fremont
-
Los Angeles, California, Estados Unidos, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Estados Unidos, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Estados Unidos, 90033
- Los Angeles General Medical Center
-
Modesto, California, Estados Unidos, 95355
- Memorial Medical Center
-
Newport Beach, California, Estados Unidos, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Palo Alto, California, Estados Unidos, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Estados Unidos, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Estados Unidos, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Estados Unidos, 95816
- Sutter Medical Center Sacramento
-
San Francisco, California, Estados Unidos, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Estados Unidos, 94115
- California Pacific Medical Center-Pacific Campus
-
San Mateo, California, Estados Unidos, 94401
- Mills Health Center
-
Santa Cruz, California, Estados Unidos, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Estados Unidos, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Estados Unidos, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Estados Unidos, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Englewood, Colorado, Estados Unidos, 80113
- The Melanoma and Skin Cancer Institute
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Estados Unidos, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Estados Unidos, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Estados Unidos, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Estados Unidos, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Estados Unidos, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Estados Unidos, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Aurora, Illinois, Estados Unidos, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Estados Unidos, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Estados Unidos, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Estados Unidos, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Estados Unidos, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Estados Unidos, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Lake Forest, Illinois, Estados Unidos, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Estados Unidos, 60462
- Northwestern Medicine Orland Park
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Estados Unidos, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Yorkville, Illinois, Estados Unidos, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Estados Unidos, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Estados Unidos, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Estados Unidos, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Estados Unidos, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Estados Unidos, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Estados Unidos, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Battle Creek, Michigan, Estados Unidos, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49009
- Beacon Kalamazoo Cancer Center
-
Muskegon, Michigan, Estados Unidos, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Estados Unidos, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Estados Unidos, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Estados Unidos, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Traverse City, Michigan, Estados Unidos, 49684
- Munson Medical Center
-
Wyoming, Michigan, Estados Unidos, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Burnsville, Minnesota, Estados Unidos, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Mercy Hospital
-
Edina, Minnesota, Estados Unidos, 55435
- Fairview Southdale Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Abbott-Northwestern Hospital
-
Robbinsdale, Minnesota, Estados Unidos, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Estados Unidos, 55102
- United Hospital
-
-
Missouri
-
Farmington, Missouri, Estados Unidos, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Estados Unidos, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Estados Unidos, 59901
- Logan Health Medical Center
-
Missoula, Montana, Estados Unidos, 59804
- Community Medical Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Estados Unidos, 07920
- Memorial Sloan Kettering Basking Ridge
-
-
New York
-
Camillus, New York, Estados Unidos, 13031
- Hematology Oncology Associates of CNY at Camillus
-
East Syracuse, New York, Estados Unidos, 13057
- Hematology Oncology Associates of Central New York-East Syracuse
-
Harrison, New York, Estados Unidos, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, Estados Unidos, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Estados Unidos, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Centerville, Ohio, Estados Unidos, 45459
- Miami Valley Hospital South
-
Cincinnati, Ohio, Estados Unidos, 45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland, Ohio, Estados Unidos, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Estados Unidos, 44109
- MetroHealth Medical Center
-
Dayton, Ohio, Estados Unidos, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Estados Unidos, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Estados Unidos, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Estados Unidos, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Estados Unidos, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Medical Center
-
Troy, Ohio, Estados Unidos, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Lawton, Oklahoma, Estados Unidos, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Estados Unidos, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
Willow Grove, Pennsylvania, Estados Unidos, 19090
- Asplundh Cancer Pavilion
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Avera Cancer Institute
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Estados Unidos, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- HSHS Sacred Heart Hospital
-
Green Bay, Wisconsin, Estados Unidos, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Estados Unidos, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Estados Unidos, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
Oconto Falls, Wisconsin, Estados Unidos, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Sturgeon Bay, Wisconsin, Estados Unidos, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
STEP 0 INCLUSION CRITERIA
-
Histologically proven mucosal melanoma by local pathology
-
Central PD-L1 tumor tissue submission
-
STEP 1 INCLUSION CRITERIA
-
Receipt of the central PD-L1 testing results available
- Report is required for randomization of resection R0 or R1 patients
- Testing must be started in Step 0 but results can be reported after registration for resection R2 patients
-
Disease status-Resected R0 or R1 disease patients. Patients eligible for randomization have resected R0 or R1 disease (with negative margins or positive microscopic margins) that must meet one of the following 4 criteria as defined below:
-
Regional lymph node (LN) involvement; OR
-
In-transit metastases/satellite primary disease; OR
-
Single localized, primary disease meeting one of the following site-specific requirements:
-
Head/neck - Sinonasal (including nasopharynx): any primary lesion; Nasal or oral cavity; pT4a or above, given slightly improved OS
- NOTE: Conjunctival: does not meet the qualification for eligibility
-
Anorectal - any primary lesion
-
Vaginal/cervical - any primary, as they have 5 year OS rates of 5-25%
-
Urinary tract - any primary urethral or bladder tumor
-
Penile
-
Vulvar- American Joint Committee on Cancer (AJCC) cutaneous stage IIB or higher
-
Esophageal/gallbladder - any primary
-
-
Locoregionally recurrent following prior resection, meeting at least one of the above criteria
-
In addition, patients must have undergone cross-sectional imaging of the brain, chest, abdomen and pelvis with no evidence of distant metastatic disease
-
-
Disease status-Non-resected R2 or metastatic disease patients
- Non-resected R2 or metastatic disease that is assessable and measurable radiographically or by physical examination
-
Prior Treatment:
- No prior systemic checkpoint inhibitor therapy of mucosal melanoma, including in the adjuvant setting, is allowed. Prior adjuvant chemotherapy or interferon is allowed.
- No other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator. Exceptions may allow for adjuvant no evidence of disease (NED) cancers undergoing hormone based therapy may be eligible pending the other eligibility criteria are met and the principal investigator (PI) affirms the hormonal agent would not change the melanoma response.
- Any radiation must have completed 28 days prior to randomization and the patient must have adequately recovered from its effects.
- For resectable patients only: Surgery must have completed 28 days prior to randomization.
- For resectable patients only: Surgery must have completed no more than 84 days prior to randomization.
-
Not pregnant and not nursing, because this study has an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance (CrCl) >= 50mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Albumin >= 2.8 g/dL
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
-
No cardiovascular disease, including:
- No history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft (CABG) coronary angioplasty, or stenting within 6 months prior to study entry.
- No history of current class II or higher congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system.
- No refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg despite adequate attempts at anti-hypertensive therapy.
- No history of myocarditis.
- No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, history of Mobitz II second degree or third degree heart block without a permanent pacemaker in Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within the past 3 months.
- No corrected QT interval by Fridericia's formula (QTcF) > 500 msec. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard.
-
No underlying hematologic issues, including:
- Congenital bleeding diathesis
- Gastrointestinal (GI) bleeding requiring intervention within the past 6 months, unless directly related to mucosal melanoma
- Active hemoptysis within 42 days prior to study enrollment.
- Active tumor lesions with cavitations or tumor lesions which invade, encase, or abut major blood vessels. The anatomic location and characteristics of primary tumors or metastases as well as the medical history should be carefully reviewed in the selection of subjects for treatment with cabozantinib/placebo.
- Pulmonary emboli or deep vein thromboses (DVT) that require an active anticoagulation regimen.
- No known or suspected history of cytopenia (low white blood cell [WBC], hemoglobin or platelet count) of greater than 3 months duration with an unknown cause, myelodysplastic syndrome, or hematologic malignancies.
-
No clinical, laboratory or radiographic evidence of an active bacterial, fungal, or viral infection requiring treatment at the time of pre-registration (e.g., active symptoms of COVID-19 infection or a post-infectious symptomatic autoimmune syndrome, serious bacterial infections requiring antibiotics).
-
No known or suspected gastrointestinal disorder affecting absorption of oral medications.
-
Comorbid conditions:
-
No active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (> 10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
-
No history of autoimmune motor neuropathy (e.g., Guillain-Barre syndrome, myasthenia gravis) or non-infectious pneumonitis.
-
No history of severe allergic reactions to an unknown allergen or any components of the study drugs or its excipients.
-
No history of gastrointestinal perforation or abdominal fistula.
-
No clinically suspected central nervous system (CNS) (leptomeningeal or parenchymal) metastases. Patients with a history of CNS metastasis(s) will be allowed as long as
- The metastatic site(s) were adequately treated as demonstrated by clinical and radiographic improvement, AND
- The patient has recovered from the intervention (no residual adverse events > Common Terminology Criteria for Adverse Events [CTCAE] grade 1), AND
- The patient has remained without occurrence of new or worsening CNS symptoms for a period of 28 days prior to enrollment.
-
No history of seizure or any condition that may increase the patient's seizure risk (e.g., prior cortical stroke, significant brain trauma) within 2 years.
-
No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction.
-
No untreated spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression. Spinal metastases must have completed planned radiation or surgical therapy prior to registration.
-
-
Concomitant medications:
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 5 days prior to the start of study treatment.
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 5 days prior to the start of study treatment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm 1 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Given PO
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Undergo bone scan
Outros nomes:
Undergo blood and tissue sample collection
Outros nomes:
|
|
Comparador Ativo: Arm 2 (nivolumab, placebo)
Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Undergo bone scan
Outros nomes:
Undergo blood and tissue sample collection
Outros nomes:
Given PO |
|
Experimental: Arm 3 (nivolumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo bone scans, as well as optional blood and tissue sample collection throughout the trial. |
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Given PO
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Undergo bone scan
Outros nomes:
Undergo blood and tissue sample collection
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recurrence free survival (RFS)
Prazo: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Will evaluate RFS of single agent adjuvant nivolumab plus placebo compared to the combination treatment of adjuvant nivolumab plus cabozantinib in patients with resected mucosal melanoma. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall survival (OS)
Prazo: Number of days from registration until death (due to any cause, assessed up to 5 years
|
Will be evaluated utilizing the Kaplan-Meier (KM) method and, when appropriate, cox proportional hazards models. Median OS is calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model is built to compare arms 1 and 2 with respect to OS. |
Number of days from registration until death (due to any cause, assessed up to 5 years
|
|
RFS
Prazo: Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
Median RFS will be calculated (along with 95% Confidence intervals) using the KM method. A Cox proportional hazards model will also be built to compare arms 1 and 2 with respect to RFS, with and without stratifying for PD-L1 categorization. For non-resected cohort, If a patient in this group has surgery, their RFS data will be censored at the time of surgery. |
Number of days from registration until either local or distant recurrence or death (due to any cause), assessed up to 5 years
|
|
Progression free survival
Prazo: Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
Will be evaluated in multiple settings utilizing the KM method and, when appropriate, cox proportional hazards models. |
Number of days from registration until either radiographic or clinical progression or death (due to any cause), assessed up to 5 years
|
|
Objective response rate (Arm 3)
Prazo: Up to 5 years
|
Will assess this endpoint utilizing a two-stage Simon that looks to improve from a rate of 20% to 47%. |
Up to 5 years
|
|
Duration of response (Arm 3)
Prazo: Time from the first evidence of response until progression, assessed up to 5 years
|
A KM analysis is performed to calculate the median duration of response and 95% confidence intervals are constructed. |
Time from the first evidence of response until progression, assessed up to 5 years
|
|
Incidence of adverse events
Prazo: Up to 5 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be summarized. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Alexander N Shoushtari, Alliance for Clinical Trials in Oncology
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Técnicas de química, analíticas
- Análise de espectro
- Nivolumabe
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- Cabozantinib
Outros números de identificação do estudo
- NCI-2021-11794
- U10CA180821 (Concessão/Contrato do NIH dos EUA)
- NCI-2021-11794 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- A091903 (Outro identificador: CTEP)
- A091903 (Outro identificador: Alliance for Clinical Trials in Oncology)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .